MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate
Chronic myeloid leukemia (CML), a hematopoietic neoplasm arising from the fusion of BCR (breakpoint cluster region) gene on chromosome 22 to the ABL (Abelson leukemia virus) gene on chromosome 9 (BCR-ABL1 oncogene), originates from a small population of leukemic stem cells with extensive capacity fo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/19/10216 |
| _version_ | 1797516413981687808 |
|---|---|
| author | Juliana R. B. Martins Leonardo N. Moraes Sarah S. Cury Juliana Capannacci Robson Francisco Carvalho Célia Regina Nogueira Newton Key Hokama Paula O. M. Hokama |
| author_facet | Juliana R. B. Martins Leonardo N. Moraes Sarah S. Cury Juliana Capannacci Robson Francisco Carvalho Célia Regina Nogueira Newton Key Hokama Paula O. M. Hokama |
| author_sort | Juliana R. B. Martins |
| collection | DOAJ |
| description | Chronic myeloid leukemia (CML), a hematopoietic neoplasm arising from the fusion of BCR (breakpoint cluster region) gene on chromosome 22 to the ABL (Abelson leukemia virus) gene on chromosome 9 (BCR-ABL1 oncogene), originates from a small population of leukemic stem cells with extensive capacity for self-renewal and an inflammatory microenvironment. Currently, CML treatment is based on tyrosine kinase inhibitors (TKIs). However, allogeneic hematopoietic stem cell transplantation (HSCT-allo) is currently the only effective treatment of CML. The difficulty of finding a compatible donor and high rates of morbidity and mortality limit transplantation treatment. Despite the safety and efficacy of TKIs, patients can develop resistance. Thus, microRNAs (miRNAs) play a prominent role as biomarkers and post-transcriptional regulators of gene expression. The aim of this study was to analyze the miRNA profile in CML patients who achieved cytogenetic remission after treatment with both HSCT-allo and TKI. Expression analyses of the 758 miRNAs were performed using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Bioinformatics tools were used for data analysis. We detected miRNA profiles using their possible target genes and target pathways. MiR-125a-3p stood out among the downregulated miRNAs, showing an interaction network with 52 target genes. MiR-320b was the only upregulated miRNA, with an interaction network of 26 genes. The results are expected to aid future studies of miRNAs, residual leukemic cells, and prognosis in CML. |
| first_indexed | 2024-03-10T07:00:49Z |
| format | Article |
| id | doaj.art-7c8a2c6ce8534cbf9bb7057100873098 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T07:00:49Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7c8a2c6ce8534cbf9bb70571008730982023-11-22T16:06:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-09-0122191021610.3390/ijms221910216MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib MesylateJuliana R. B. Martins0Leonardo N. Moraes1Sarah S. Cury2Juliana Capannacci3Robson Francisco Carvalho4Célia Regina Nogueira5Newton Key Hokama6Paula O. M. Hokama7Department of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, BrazilDepartment of Bioprocesses and Biotechnology, School of Agriculture, São Paulo State University (FCA-UNESP), Botucatu 18610-034, BrazilDepartment of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (IBB-UNESP), Botucatu 18618-970, BrazilDepartment of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, BrazilDepartment of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (IBB-UNESP), Botucatu 18618-970, BrazilDepartment of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, BrazilDepartment of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, BrazilDepartment of Internal Medicine, Botucatu Medical School, São Paulo State University (FMB-UNESP), Botucatu 18618-687, BrazilChronic myeloid leukemia (CML), a hematopoietic neoplasm arising from the fusion of BCR (breakpoint cluster region) gene on chromosome 22 to the ABL (Abelson leukemia virus) gene on chromosome 9 (BCR-ABL1 oncogene), originates from a small population of leukemic stem cells with extensive capacity for self-renewal and an inflammatory microenvironment. Currently, CML treatment is based on tyrosine kinase inhibitors (TKIs). However, allogeneic hematopoietic stem cell transplantation (HSCT-allo) is currently the only effective treatment of CML. The difficulty of finding a compatible donor and high rates of morbidity and mortality limit transplantation treatment. Despite the safety and efficacy of TKIs, patients can develop resistance. Thus, microRNAs (miRNAs) play a prominent role as biomarkers and post-transcriptional regulators of gene expression. The aim of this study was to analyze the miRNA profile in CML patients who achieved cytogenetic remission after treatment with both HSCT-allo and TKI. Expression analyses of the 758 miRNAs were performed using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Bioinformatics tools were used for data analysis. We detected miRNA profiles using their possible target genes and target pathways. MiR-125a-3p stood out among the downregulated miRNAs, showing an interaction network with 52 target genes. MiR-320b was the only upregulated miRNA, with an interaction network of 26 genes. The results are expected to aid future studies of miRNAs, residual leukemic cells, and prognosis in CML.https://www.mdpi.com/1422-0067/22/19/10216chronic myeloid leukemiaallogeneic hematopoietic stem cell transplantationimatinib mesylatemiRNAsmiR-125a-3pmiR-320b |
| spellingShingle | Juliana R. B. Martins Leonardo N. Moraes Sarah S. Cury Juliana Capannacci Robson Francisco Carvalho Célia Regina Nogueira Newton Key Hokama Paula O. M. Hokama MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate International Journal of Molecular Sciences chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation imatinib mesylate miRNAs miR-125a-3p miR-320b |
| title | MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate |
| title_full | MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate |
| title_fullStr | MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate |
| title_full_unstemmed | MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate |
| title_short | MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate |
| title_sort | mir 125a 3p and mir 320b differentially expressed in patients with chronic myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation and imatinib mesylate |
| topic | chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation imatinib mesylate miRNAs miR-125a-3p miR-320b |
| url | https://www.mdpi.com/1422-0067/22/19/10216 |
| work_keys_str_mv | AT julianarbmartins mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT leonardonmoraes mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT sarahscury mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT julianacapannacci mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT robsonfranciscocarvalho mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT celiareginanogueira mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT newtonkeyhokama mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate AT paulaomhokama mir125a3pandmir320bdifferentiallyexpressedinpatientswithchronicmyeloidleukemiatreatedwithallogeneichematopoieticstemcelltransplantationandimatinibmesylate |